Patent ID: 8905997

Claim:
A method for decreasing the rate of neointimal hyperplasia (NIH) formation in a blood vessel of a patient receiving a bare metal stent in a lesion of said blood vessel, comprising: administering a composition comprising therapeutic particles, wherein said therapeutic particles comprise: about 1 to about 20 mole percent PLA-PEG-basement vascular membrane targeting peptide, wherein the targeting peptide comprises PLA having a number average molecular weight of about 15 to about 20 kDa and PEG having a number average molecular weight of about 4 to about 6 kDa; about 10 to about 25 weight percent anti-neointimal hyperplasia (NIH) agent; about 50 to about 90 weight percent non-targeted poly-lactic acid-PEG, wherein the therapeutic particles are capable of releasing the anti-NIH agent to a basement vascular membrane of a blood vessel for at least about 8 hours when the therapeutic particles are placed in the blood vessel.